Anticoagulation in Pregnancy

Primary Recommendation

For pregnant patients requiring anticoagulation, low-molecular-weight heparin (LMWH) is the preferred agent for both treatment and prophylaxis of venous thromboembolism, with specific regimens tailored to the underlying indication—mechanical heart valves require the most aggressive approach, antiphospholipid syndrome requires combination therapy with aspirin, and atrial fibrillation management must balance maternal stroke risk against fetal safety. 1

General Principles: Why LMWH is Preferred

LMWH does not cross the placenta, making it safe for the fetus, unlike warfarin which causes embryopathy in the first trimester and fetal bleeding risk near delivery 2, 3, 4
LMWH has superior safety and convenience compared to unfractionated heparin (UFH), with lower rates of heparin-induced thrombocytopenia and osteoporosis, plus no need for routine aPTT monitoring 5, 3
Warfarin must be avoided in the first trimester (teratogenic before 13 weeks) and after 36 weeks (risk of fetal intracranial hemorrhage) 1, 6, 4
Direct oral anticoagulants (DOACs) are absolutely contraindicated throughout pregnancy due to safety concerns and lack of data 7, 6

Venous Thromboembolism (VTE)

Acute VTE Treatment During Pregnancy

Therapeutic-dose LMWH (e.g., enoxaparin 1 mg/kg subcutaneously twice daily) should be continued throughout pregnancy and for at least 6 weeks postpartum, for a minimum total treatment duration of 6 months 1, 2, 8
Alternative: Adjusted-dose UFH subcutaneously every 12 hours, targeting mid-interval aPTT at least twice control or anti-Xa level 0.35-0.70 units/mL 1

VTE Prophylaxis: History of Prior VTE

The approach depends on VTE history and thrombophilia status:

Single prior VTE with transient risk factor (no longer present):

Antepartum clinical surveillance only
Postpartum anticoagulant prophylaxis for 6 weeks 1, 2, 8

Single prior VTE with thrombophilia or strong family history:

Antepartum prophylactic or intermediate-dose LMWH (e.g., enoxaparin 40 mg daily or 40 mg twice daily)
Postpartum anticoagulation for 6 weeks 1, 2, 8

Multiple prior VTE episodes or on long-term anticoagulation:

Antepartum adjusted-dose, intermediate-dose, or 75% therapeutic-dose LMWH throughout pregnancy
Resume long-term anticoagulation postpartum 1, 2, 8

VTE Prophylaxis: Thrombophilia Without Prior VTE

Antithrombin deficiency (highest risk thrombophilia):

Both antepartum and postpartum prophylaxis recommended 1, 2

Homozygous factor V Leiden or prothrombin G20210A mutation:

Antepartum clinical vigilance
Postpartum prophylaxis for 6 weeks with prophylactic or intermediate-dose LMWH 1

All other thrombophilias without family history:

Antepartum and postpartum clinical vigilance only (no pharmacologic prophylaxis) 1

Antiphospholipid Syndrome (APS)

Diagnostic Criteria Must Be Met

Both laboratory AND clinical criteria are required for treatment: 7, 6

Laboratory: Persistent antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, or anti-β2-glycoprotein I) on two occasions ≥12 weeks apart
Clinical: Either ≥3 early pregnancy losses (before 10 weeks), ≥1 late loss (after 10 weeks), or history of thrombosis

Obstetric APS (Recurrent Pregnancy Loss, No Prior Thrombosis)

Prophylactic or intermediate-dose LMWH (e.g., enoxaparin 40 mg daily) PLUS low-dose aspirin 75-100 mg daily starting as soon as pregnancy is confirmed, continued throughout pregnancy and for 6 weeks postpartum (Grade 1B) 1, 7, 6
Aspirin should ideally be started pre-conceptionally or before 16 weeks gestation 6

Thrombotic APS (History of Prior Thrombosis)

Therapeutic-dose LMWH (or 75% therapeutic dose) PLUS low-dose aspirin 75-100 mg daily throughout pregnancy and postpartum 7, 6
For women on chronic warfarin attempting pregnancy: perform frequent pregnancy tests and switch to LMWH immediately upon positive test 6, 8

Asymptomatic Antiphospholipid Antibody-Positive Patients

Do NOT routinely anticoagulate—these patients receive only prophylactic aspirin 81-100 mg daily for preeclampsia prevention 7, 6

Critical Pitfall to Avoid

Patients with only two miscarriages without confirmed antiphospholipid antibodies should NOT receive antithrombotic prophylaxis (Grade 1B recommendation against treatment) 1, 6

Mechanical Heart Valves (Highest Risk Scenario)

Three Acceptable Regimens (All Grade 1A)

The choice is highly individualized based on valve type, position, and patient values regarding maternal vs. fetal risk: 1

Option A: Adjusted-dose LMWH throughout pregnancy

LMWH twice daily, adjusted to achieve manufacturer's peak anti-Xa level 4 hours post-injection
Safest for fetus but may have higher maternal thrombosis risk 1

Option B: Adjusted-dose UFH throughout pregnancy

Subcutaneous UFH every 12 hours, targeting mid-interval aPTT ≥2× control or anti-Xa 0.35-0.70 units/mL 1

Option C: Heparin/warfarin hybrid approach

UFH or LMWH until week 13
Switch to warfarin from week 13 until week 36
Resume UFH or LMWH from week 36 until delivery 1

Very High-Risk Mechanical Valves

For older-generation prostheses in mitral position or history of thromboembolism:

Consider warfarin throughout pregnancy with substitution by UFH or LMWH close to delivery (Grade 2C)
This prioritizes maternal survival over fetal risk, but requires extensive counseling 1

Adjunctive Aspirin

Add low-dose aspirin 75-100 mg daily to any anticoagulation regimen in pregnant women with prosthetic valves at high thromboembolism risk (Grade 2C) 1, 9

Atrial Fibrillation

While the provided guidelines focus primarily on VTE, mechanical valves, and APS, the general principles apply:

LMWH is the anticoagulant of choice if stroke risk is high (CHA₂DS₂-VASc ≥2)
Prophylactic to intermediate-dose LMWH throughout pregnancy
Consider adding low-dose aspirin 75-100 mg daily for additional stroke prevention 9
Rate control is essential—beta-blockers (metoprolol, labetalol) are safe in pregnancy

Peripartum Management

Timing of LMWH Discontinuation

Stop LMWH at least 24 hours before planned delivery, cesarean section, or neuraxial anesthesia to minimize bleeding risk 7, 6
For spontaneous labor, discontinue LMWH when contractions begin

Resumption of Anticoagulation

Resume LMWH 12-24 hours after vaginal delivery or 24 hours after cesarean section once hemostasis is secured 7, 6
Use therapeutic dosing for thrombotic APS or history of VTE
Continue for at least 6 weeks postpartum 1, 7

Preeclampsia Prophylaxis

For women at risk for preeclampsia, low-dose aspirin 75-100 mg daily throughout pregnancy starting from the second trimester is recommended (Grade 1B) 1, 9
This reduces preeclampsia risk by 17% (NNT 61), preterm birth by 8-9%, and fetal/neonatal death by 14-15% 9

Monitoring and Safety

LMWH Monitoring

Routine anti-Xa monitoring is generally not required for prophylactic dosing 5
For therapeutic dosing or extreme body weights, consider peak anti-Xa levels 4 hours post-injection (target 0.6-1.0 units/mL for twice-daily dosing) 1
Check platelet count periodically to screen for heparin-induced thrombocytopenia 5

Contraindications to Inherited Thrombophilia Screening

Do NOT screen for inherited thrombophilia in women with a history of pregnancy complications alone (Grade 2C) 1
Screening is only indicated if there is personal or strong family history of VTE

Key Clinical Pitfalls

Never use warfarin in first trimester or after 36 weeks—causes embryopathy and fetal bleeding 6, 4
Never use DOACs in pregnancy—contraindicated due to safety concerns 7, 6
Do not anticoagulate asymptomatic antiphospholipid antibody carriers—aspirin only 7, 6
Do not give antithrombotic prophylaxis for recurrent miscarriage without confirmed APS or thrombophilia (Grade 1B against) 1
Mechanical heart valves require aggressive anticoagulation—underdosing risks catastrophic valve thrombosis and maternal death 1

What is the recommended anticoagulation strategy during pregnancy for patients requiring treatment or prophylaxis of venous thromboembolism, antiphospholipid syndrome, atrial fibrillation, or mechanical heart valves?

Help us tailor your experience